Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Tax Provisions (2019 - 2025)

Catalyst Pharmaceuticals' Tax Provisions history spans 7 years, with the latest figure at $19.2 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 30.67% year-over-year to $19.2 million; the TTM value through Dec 2025 reached $69.2 million, up 11.91%, while the annual FY2025 figure was $69.2 million, 11.91% up from the prior year.
  • Tax Provisions reached $19.2 million in Q4 2025 per CPRX's latest filing, up from $18.3 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $29.7 million in Q4 2023 to a low of -$10.2 million in Q4 2022.
  • Average Tax Provisions over 5 years is $9.4 million, with a median of $7.2 million recorded in 2022.
  • Peak YoY movement for Tax Provisions: soared 506.69% in 2021, then crashed 391.84% in 2022.
  • A 5-year view of Tax Provisions shows it stood at $3.5 million in 2021, then tumbled by 391.84% to -$10.2 million in 2022, then surged by 390.12% to $29.7 million in 2023, then dropped by 6.64% to $27.7 million in 2024, then crashed by 30.67% to $19.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Tax Provisions are $19.2 million (Q4 2025), $18.3 million (Q3 2025), and $17.2 million (Q2 2025).